Company: IOBT
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047744
Chunk: 137

Company: IO Biotech, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 5
Chunk 137
---
 S-1 (File No. 333-260301), which was filed with the SEC on October 15, 2021 and subsequently amended and declared effective on November 4, 2021, and the prospectus included therein (the “Prospectus”). The underwriters of the IPO were Morgan Stanley & Co. LLC, Jefferies LLC, Cowen and Company, LLC and Kempen & Co U.S.A, Inc.    

126

We raised $103.3 million in net proceeds from the IPO after deducting underwriting discounts and commissions of $8.0 million and other offering expenses of $3.8 million payable by us. No underwriting discounts and commissions or offering expenses were paid directly or indirectly to any of our directors of officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.  

There has been no material change in the planned use of proceeds from our IPO, as described in the Prospectus. As of December 31, 2024, the Company has fully used the proceeds of our IPO, and there was no material change in the use of proceeds as described in the Prospectus.

Purchases of Equity Securities by the Issuer and Affiliated Parties

None.